Comorbidities Key to Serious Infections With IBD Treatment

Older IBD patients with comorbidities are less likely to be hospitalized due to an infection if they are treated with vedolizumab or ustekinumab than with an anti-TNF agent, suggests a US study.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Danaj Lukin ,Bharati Kochar ,Colitis Foundation ,Jill Roberts Center ,Chleck Family Foundation ,National Institutes Of Health ,Theamerican Journal ,Massachusetts General Hospital ,Medscape Medical News ,World Study ,Older Adults With ,Charlson Comorbidity Index ,Inflammatory Bowel Disease ,New York City ,National Institutes ,Chleck Family ,Crohns Disease ,Anti Tnf ,Anti Tumor Necrosis Factor ,Biologic Therapy ,Ulcerative Colitis ,Nflammatory Bowel Disease Ibd ,Bd ,Monoclonal Antibody ,Etuximab ,Ituximab ,Hospitals ,Inpatient Care ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Immunocompromi ,